Health Care • Biotechnology: Commercial Physical & Biological Resarch
$1.73 ▲ +0.02
(+1.17%)
MKT CAP: $178.5M • VOL: 1.14M
52W L $1 52W H $2
MXCT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $21.0M | $22.2M | $19.5M |
| YoY Revenue Growth % | -5.7% | +13.9% | — |
| Gross Profit | $26.8M | $31.5M | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.9M | -$51.2M | -$48.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$44.6M | -$41.1M | -$37.9M |
| EBITDA (Normalized) | -$50.5M | -$49.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$34.4M | -$27.6M | -$21.7M |
| Capital Expenditures (CapEx) | $1.8M | $1.7M | — |
| Free Cash Flow (FCF) | -$36.2M | -$29.3M | -$21.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -27.1% | -22.7% | — |
| Cash & Short-Term Equivalents | $20.1M | $27.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $171.5M | $206.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MXCT.